Revision 1

Store at -20C

#14210

SGLT2 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	46-75	Rabbit	#P31639	6524

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. *Do not aliquot the antibody.*

Specificity/Sensitivity

SGLT2 Antibody recognizes endogenous levels of total SGLT2 protein. This antibody does not recognize SGLT1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human SGLT2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Na(+)/glucose cotransporter 2 (SGLT2) is one of the two main glucose transporters in the kidney proximal convoluted tubule. It is activated by Protein Kinase A and Protein Kinase C, likely through phosphorylation of Ser624 (1,2). SGLT2 is responsible for the majority of glucose reabsorption in the kidney (3,4), and mutations in SGLT2 are known to cause familial renal glucosuria (5,6). SGLT2 is a therapeutic target for type 2 diabetes. Inhibitors of SGLT2 have been developed in order to treat people with type 2 diabetes (7).

Background References

1. Feric, M. et al. (2011) *Am J Physiol Cell Physiol* 300, C755-70.
2. Ghezzi, C. and Wright, E.M. (2012) *Am J Physiol Cell Physiol* 303, C348-54.
3. Wells, R.G. et al. (1992) *Am J Physiol* 263, F459-65.
4. Wright, E.M. (2001) *Am J Physiol Renal Physiol* 280, F10-8.
5. Lee, H. et al. (2012) *Pediatr Nephrol* 27, 1091-5.
6. Andrianesis, V. and Doupis, J. (2013) *Expert Rev Clin Pharmacol* 6, 519-39.
7. Sheridan, C. (2012) *Nat Biotechnol* 30, 899-900.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.